News
FDA plans to phase out animal testing in drugs in what it calls a ‘paradigm shift’
On Thursday, shares in Charles River Laboratories, a leading contract research organizations that has stirred controversy over its use of non-human primates, plunged 28 percent after the FDA issued its announcement.
Researchers in pharma and beyond have historically glommed onto a limited number of disease targets, limiting innovation. AI ...
Recent advances in biotechnology now provide a pathway to producing living human ... These could revolutionize medical research and drug development, greatly reducing the need for animal testing ...
To have any impact, patient engagement needs to start with the drug development pathway, not at the point of licensing. That’s especially true in the rare disease space, where the unmet need is ...
Since the Orphan Drug Act went into effect in 1983, more than 600 drugs have been approved for rare diseases, according to ...
The drug "hijacks" a normal developmental pathway to trigger cancer cell death ... retinoic acid signaling in the same ...
How can real world evidence (RWE) improve the drug development pathway, from discovery to approval, and boost access to treatment? What are the challenges and barriers to using this data to guide ...
SOLVE FSHD Announces Strategic Collaboration with Transcripta Bio to Advance Drug Discovery for FSHD
repurposed drug candidates that could reach patients sooner than traditional drug development pathways. About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback